RxDoctor Payments Data

Robins Newton, MD

Neurology · Birmingham, ALNPI 1013001148

Payments from drug & device makers

$22,974in general payments, 2019–2025

Across 1,284 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • UCB, Inc.$2K
  • Lilly USA, LLC$1K
  • Lundbeck LLC$1K
  • Pfizer$1K
  • Neurocrine Biosciences, Inc.$1K
  • plus $11K from 39 others

What the payments were for

  • Speaking & faculty fees$2391%
  • Food & beverage$22,73599%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,974 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$123,282
Medicare patients
316
Services billed
3,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant47$70,178
Emgality PenGalcanezumab-Gnlm79$69,876
Aimovig AutoinjectorErenumab-Aooe64$52,255
Nurtec OdtRimegepant Sulfate32$35,920
UbrelvyUbrogepant30$29,249
Memantine Hcl660$23,412
Lacosamide106$19,021
Levetiracetam302$7,265
Ajovy AutoinjectorFremanezumab-Vfrm11$7,220
Frovatriptan Succinate25$5,521
Memantine Hcl ErMemantine Hcl20$4,771
Carbidopa-LevodopaCarbidopa/Levodopa108$4,302
Levetiracetam ErLevetiracetam41$2,664
Eletriptan HbrEletriptan Hydrobromide23$2,637
Lamotrigine116$2,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$4,749$99,42777 claims
PfizerNurtec Odt$1,271$35,92032 claims
Upsher-smith Laboratories LLCTopiramate$481$1,297122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 neurology providers in Alabama.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →